This narrative review of the literature aims to assess the impact of COVID-19 on the younger age group in terms of the Global mortality of COVID-19 in comparison to Nepal. An extensive literature survey of English literature was conducted using Pubmed, Medline, Google Scholar, Embase, WHO Nepal Situation Updates on COVID-19, Situation update report, Ministry of Health and Population-Nepal from January 25, 2020 to June20, 2020. According to the Ministry of Health and population of The Government of Nepal, as of June 20 , 2020, out of a total of 8,605 laboratory confirmed cases reported to date, the pattern shows that most of the cases fell into the cohort of 21-30 years (37.72%), followed by 11-20 years (24.35 %), 31-40 years (21.97%) and 41-50 years (9.2%). To date Nepal has recorded a total of twenty-two deaths. At first evaluation thesefigures may not strike one as alarming, but on further investigation it is noted that the mean age is 42. 32 ± 19.632 SD years, and out of which male patients accounted for 77.3% and female accounted for 22.7%. The current situation of COVID-19 and how it develops in Nepal should be closely monitored and could be of international concern as it may be the early indicator of a changing pattern in COVID-19 infections. Nepal maytherefore act as a global watch dog, due to the fact that the world could very possibly expose the younger age group under the notion that they are more resilient to the virus, when in reality that notion may be changing. This trend must be monitored and further investigated in order to establish the risk of the events unfolding in Nepal.

Background: The world has a current total of 6,663,304 confirmed cases of COVID-19 with a death count of 392,802 deaths according to the WHO (6 June 2020). Various risk factors for the acquisition and subsequent development of deadly complications due to the virus have been established. One such risk factor is the presence of cardiovascular disease, particularly hypertension as a comorbidity. It must be noted that JNC 8 advise the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers as first line drugs for the management of hypertension. ARDS is caused by the activation of angiotensin I, angiotensin II and AT1 receptor pathway, however stimulation of Mas receptor, MRGPR receptors, AT2 receptor and the ACE-2-angiotensin (1-7), pathways is found to be defensive.  Mas receptor exerts an inhibitory effect on inflammation and cellular growth and vascular mechanisms.  This research aims to examine the relationship between ACE inhibitors and the risk of COVID-19 infections with the goal of determining whether this relationship is spurious in association or whether it is causative in nature? More specifically, in this research article we will determine whether the SARS-CoV-2 virus has an affinity for ACE 2 receptors in humans. Furthermore, it will be determined whether ACE inhibitors would inhibit or facilitate an imminent COVID-19 infection in individuals as well as to  determine whether patients currently using ACE inhibitors should continue or discontinue the drug therapy in order to minimize their susceptibility to acquiring COVID-19, and whether patients should start ACE inhibitor therapy if required during this pandemic. Conclusion: It is evident that ACE 2 receptors are the portal of entry for SARS-CoV-2. It is recommended that the use of RAAS inhibitors, viz ACE inhibitors and angiotensin receptor blockers is not stopped or decreased despite the ongoing pandemic as the results thereof may lead to the worsening of the patient’s comorbidity and may hasten death.

A mutation is defined as an alteration in the DNA or RNA sequences of a genome which may consequently confer a new phenotypic and or genotypic advantage both increasing the virulence as well as the survival of a virus or pathogen. At this current point in time there are 4 known major variants of the original SARS-CoV-2 virus, namely the English variant, the South African variant, the Brazilian variant and a variant similar to that of the South African variant found in North America, all of which have varying levels of resistance and infectivity. It is evident that the SARS-CoV-2 variants pose an international health risk, the mutations of E484K and N501Y are the two most implicated mutations. E484K being the most concerning as it aids in immune evasion and drastically causes the efficacy of the current vaccines to be reduced by large margins. The most worrisome variant is the South African or B.1.351 which harbors the above mutations. it is of the upmost importance that targeted vaccines are synthesized to ensure the that immunized individuals have effective protection against these variants. Until these specific targeted vaccines are synthesized the current vaccines offer little long-term protection, however do confer a level of immunity to stop severe infections. It is thus advised that current vaccination programs should continue in earnest as a degree of protection is conferred.

Background: A multitude and wide array of various drugs have been postulated and some even attempted to be used as effective treatments against the virus.  The drugs have ranged from antimalarials used in India as a prophylaxis to the disease; namely chloroquine and hydroxychloroquine, to the use of broad-spectrum antiviral drugs such as Remdesivir. Dexamethasone, a cheap, widely available, long acting corticosteroid has been gaining popularity and to some extent fame in the treatment of COVID19 patients. The benefits and use thereof were made apparent after very successful research conducted by the University of Oxford. The Recovery trial, which is one of the world’s largest clinical trials. This trial reported on June 16, 2020 that patients on Dexamethasone at a dosage of 6 mg per day for 10 days have a dramatically reduced mortality particularly in the COVID patients on ventilators. The dexamethasone proved very beneficial in the milder cases of the disease as well and reduced death by 20% in those cases. The proposed mechanism of action by which the dexamethasone drug acts is via impeding the dangerous cytokine storm, an intense immune response that severely renders the lungs damaged. This intense cytokine storm is attributed to the severe complications and respiratory failure noted in COVID19 patients. The long acting dexamethasone would suppress this autoimmune destruction and intense inflammatory reaction, thereby sparing the lungs and the patient’s life. Conclusion: It is therefore of paramount importance that the use of dexamethasone in COVID19 cases is further studied and understood. The benefits of the use of dexamethasone are undeniable and therefore the drug should be implemented into the treatment regime with a guarded approach. 

Background: Blood group antigens are present on the red blood cell surface. O, A, and B are the major blood groups. A, B, AB, and A1 are the antigens. An ample amount of research supports the close association of blood groups with diseases. A new school of thought and finding seems to be indicating that certain blood groups are more susceptible to the COVID-19 infection in comparison to others. Current evidence suggests that SARS-CoV-2 positive cases are more prevalent in individuals with blood group A as compared to those with blood group O. This finding, however, was only relevant for the Rh (+ve) positive blood types. Genetic association reveals that the ABO blood group locus and a chromosome 3 gene cluster are associated with severe acute respiratory syndrome in coronavirus (SARS-CoV-2) respiratory failure patents. This was found in an Italian- Spanish genome-wide association analysis. Various associations between the patients' blood groups when comparing the data with that of physiologically healthy individuals from the same geographical region helped to get a clear comparative picture. Associations that were cross-replicating in nature were determined at chromosome 3p21.31 and chromosome 9q34. The association at chromosome 9q34 was identified at the ABO blood group locus. The difference in the susceptibility could be correlated to the circulating anti‐A antibodies, which inhibit or interfere with the virus-cell adhesion process. Conclusion: It is evident that the research conducted to date is supportive and does suggest that humans of the Blood group O are less likely to be infected in the COVID-19 pandemic as when compared to other blood groups. The SARS-CoV-2 situation is evolving rapidly, discoveries and anomalies are being reported daily. Therefore, it is advised that more definitive and consolidatory research is to be conducted to further elucidate the underlying mechanism of action for the protection in blood group O.